Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5KI6X)

Drug Name

PRX003 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Psoriasis vulgaris	EA90	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cell adhesion molecule (CADM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ABX-MA1	DMZYVPB	Melanoma	2C30	Discontinued in Phase 1	[2]
ABS-205	DMALPDW	Neurodegenerative disorder	8A20-8A23	Terminated	[3]
CY-1748	DM0X147	Deep vein thrombosis	BD71	Terminated	[4]
ICM-3	DMDBICR	Graft-versus-host disease	4B24	Terminated	[5]
GM-7050	DMEVIP9	Inflammation	1A00-CA43.1	Terminated	[6]
Rovelizumab	DM4VCJI	Cerebrovascular disease	8B2Z	Terminated	[7]
NPC-17923	DMD01GK	Rheumatoid arthritis	FA20	Terminated	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res. 2002 Sep 1;62(17):5106-14.
3	Drug Discovery and Development for Alzheimer's Disease, 2000. Page(21).
4	US patent application no. 6,492,332, Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation.
5	Anti-tumor activity of an ICAM-3 antibody (ICM3) Against human leukemic xenograft tumors in nude mice. Volume 28, Issue 7, Supplement 1, 1 July 2000, Pages 59-60.
6	US patent application no. 6,673,908, Tumor necrosis factor receptor 2.
7	Rovelizumab (ICOS Corp). IDrugs. 2000 Apr;3(4):442-6.
8	Inhibition of platelet-activating factor-induced leukocyte adhesion in vivo by a leumedin. Eur J Pharmacol. 1993 Mar 2;232(2-3):169-72.